Open Nav

Please submit your session questions in advance at


  • Wolfgang Söhngen, PAION AG

PAION AG is a publicly listed specialty pharmaceutical company developing and aiming to commercialize innovative drugs for out-patient and hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic drug candidate for which PAION has completed the clinical development for use in procedural sedation in the U.S. Outside the U.S., PAION is currently focused on the development of remimazolam for general anesthesia. Development of remimazolam for intensive care unit (ICU) sedation is also part of the longer-term life-cycle plan for remimazolam.

  • Date:Monday, February 11
  • Time:2:30 PM - 2:45 PM
  • Room:Chelsea
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23533
  • Goal for Presentation:Investor outreach
  • Company
  • Company HQ City:Aachen
  • Company HQ Country:Germany
  • Market Cap:150 Mio. €
  • Ticker:PA8
  • Exchange:Xetra
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:Remimazolam
  • Development Phase of Primary Product:NDA Preparation / In Review
Wolfgang Söhngen